Human Papillomavirus (HPV) Vaccine Market Size, Future Prospects & Competitive Analysis, through 2025

Human papillomavirus (HPV) is a cluster of additional 150 related viruses. Each human papillomavirus virus in this big cluster gives a number that is termed as its HPV type. HPV is termed for the growth (papillomas) of certain HPV types which can cause. HPV contagions cause almost all types of cervical cancers and is the second most common cause of death in women due to cancer globally. Around 10 million cancer cases, diagnosed every year around the world and out of this 10 million cases about more than 15% are due to contagious agents. Infection by HPVs accounts for around 30% of tumors (around 5% of all type of cancers), with helicobacter pylori, hepatitis C, and hepatitis B viruses collectively account for additional 60% cases of cancers owing to contagious etiology.

Read Report Overview: https://www.transparencymarketresearch.com/human-papillomavirus-vaccine-market.html

HPVs infect the stratified flattened epithelial cells of mucous and skin membranes, which cause benign injuries, some of HPVs have the potential to develop to invasive cancer. HPVs are non-enveloped, minor viruses having about 8 kb spherical genome codes two essential proteins such as L1 & L2 that form several nonstructural proteins, and viral capsid that are significant for the life cycle of human papillomavirus however not combined into virions. Among all type of cancers caused by the HPV infection, cervical cancer is a major type of cancer that accounts around 10% cancer cases of several other type of cancer in women globally. It is the second most common cause of death caused due to cancer, after breast cancers, among women. Time between HPV infection and malignant development usually minimum 10 years and is normally longer. Cervical cancer is uncommon among women under the age of 25 years. The incidence rate increases progressively among women of more than 25 years of age. Incidence rate is the highest in women over 40 years of age. Approximately 80% of cervical cancers have been observed in under developed countries, owing to the lack of sufficient resources for high-quality screening programs for this cancer, which identify cervical defects via testing for the presence of cervical HPV DNA or by Pap smear testing.

Download Brochure of Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=37085

According to WHO report 2017, in year 2006, world’s first prophylactic vaccine (quadrivalent vaccine) for immunization against human papillomavirus (HPV) became available. The global HPV vaccines market is now well-established; however, coverage rates of vaccines among the traditional target population of teenage girls remains persistently low. Primarily, HPV vaccines were developed and promoted to prevent cervical cancer. Stronger support from both non-government and government organizations, such as UNICEF and WHO, development of novel vaccines with improved effectiveness, safety, and easy availability of vaccines are anticipate to drive the global HPV vaccines market in the near future. Furthermore, technological improvements in the molecular genetics field is likely to boost the human papillomavirus vaccines market. However, high cost of treatment and lack of awareness among people are factors restraining the market.

The global human papillomavirus vaccine market can be segmented based on product type, end-user, and geography. In terms of product type, the market can be classified into inactivated vaccine, attenuated vaccine, and others (subunit vaccines, DNA vaccines, toxoid vaccines, conjugated vaccines, etc.). Based on end-user, the global human papillomavirus vaccine market can be categorized into hospital, scientific research, and others. In terms of geography, the market can be divided North America, Asia Pacific, Europe, Latin America, and Middle East & Africa. North America dominated the global market due to technical advancement, increased research & development operations for the vaccine development, and awareness among people. Additionally, the development of advance diagnostic tests are a major factor driving the market in this region.

Pre Book Human Papillomavirus (HPV) Vaccine Market Research Report: https://www.transparencymarketresearch.com/checkout.php?rep_id=37085<ype=S

Key players in the global human papillomavirus vaccine market include Sanofi SA, Pfizer Inc., Merck & Co., Inc., MedImmune, Janssen Pharmaceuticals, Inc., Hualan Biological Engineering Inc., GlaxoSmithKline Plc., Bharat Biotech International Limited, Abelló A/S, Altimmune, Inc., Bavarian Nordic A/S, and BiondVax Pharmaceuticals Ltd.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

About us:
Transparency Market Research (TMR) is a U.S.-based provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.